NCT06952634View on ClinicalTrials.gov

An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 29, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Hepatic Impairment
Interventions
DRUG

ESK-001

Single oral dose of ESK-001 in participants from all cohorts

Trial Locations (4)

32809

RECRUITING

Orlando Clinical Research Center, Orlando

33104

RECRUITING

Panax Clinical Research, Miami Lakes

37920

RECRUITING

Alliance for Multispecialty Research, Knoxville

92630

RECRUITING

Orange County Research Center, Lake Forest

Sponsors

Lead Sponsor

Alumis Inc
All Listed Sponsors
lead

Alumis Inc

INDUSTRY